MTAP and renal cell carcinoma: We hypothesized that MTAP/CDKN2A-deficient features significantly correlate with sarcomatoid differentiation in RCC and predict poor outcomes, inactive targeted treatment responsiveness, and favorable responses to immune checkpoint blockade in patients with RCC.